High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS

Blood

Volumn 105, Issue 10, 2005, Pages 3817-3823

  Deconinck, Eric ^b   Foussard, Charles ^b   Milpied, Noel ^b   Bertrand, Philippe ^b   Michenet, Patrick ^b   Cornillet LeFebvre, Pascale ^b   Escoffre Barbe, Martine ^b   Maisonneuve, Herve ^b   Delwail, Vincent ^b   Gressin, Remy ^b   Legouffe, Eric ^b   Vilque, Jean Pierre ^b   Desablens, Bernard ^b   Jaubert, Jerome ^b   Ramee, Jean François ^b   Jenabian, Arash ^b   Thyss, Antoine ^b   Pourhiet Le Mevel, Annick Le ^b   Travade, Philippe ^b   Delepine, Roselyne ^b   Colombat, Philippe ^a   more..

^a CHU BRETONNEAU   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; PREDNISOLONE; PREDNISONE; TENIPOSIDE; VINCRISTINE; VINDESINE;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; INFECTION; KIDNEY CANCER; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SEPTICEMIA; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 20844457755     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-10-3920     Document Type: Article

References (44)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
2. Gibson J, Ho PJ, Joshua D. Low-grade lymphoma: the optimal timing. Transplant Proc. 2004;36:1995-1998.
3. Tse WW, Lazarus HM, Van Besien K. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant. 2004;34:929-938.
4. Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? applicability to stage III-IV patients. Ann Oncol. 1996;8:49-52.
5. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
6. Coiffier B, Bastion Y, Berger F, Felman P, Bryon PA. Prognostic factors in follicular lymphomas. Semin Oncol. 1993;20:89-95.
7. Smalley RV, Andersen JW, Hawkins MJ, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1992;327:1336-1341.
8. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma: Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. 1993;329:1608-1614.
9. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16:2332-2338.
10. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
11. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262-1268.
12. Foussard C, Deconinck E, Desablens B, et al. Improved response after fludarabine, mitoxantrone (FM) in first line treatment of patients with advanced low-grade non-Hodgkin's lymphoma (LG-LNH) as compared to prednisone, doxorubicin, vindesine, cyclophosphamide (CHEP): a randomized trial by GOELAMS group [abstract]. J Clin Oncol. 2001;20:1117.
13. Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996;14:514-519.
14. Brice P, Simon D, Bouabdallah R, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol. 2000;11:1585-1590.
15. Rohatiner AZ, Johnson PW, Price CG, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol. 1994;12:1177-1184.
16. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918-3927.
17. Colombat P, Donadio D, Fouillard L, et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant. 1994;13:157-162.
18. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325:1525-1533.
19. Colombat P, Cornillet P, Deconinck E, et al. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Bone Marrow Transplant. 2000;26:971-977.
20. Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood. 1997;89:724-731.
21. Freedman AS, Gribben JG, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996;88:2780-2786.
22. Haas R, Moos M, Mohle R, et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 1996;17:149-155.
23. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001;97:404-409.
24. Deconinck E, Foussard C, Bertrand P, et al. Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden: final results of the randomized GOELAMS 064 [abstract]. Blood. 2003;102:246a.
25. Sebban C, Belanger C, Brousse N, et al. Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 trial (G.E.L.A. Study Group) [abstract]. Blood. 2003;102:104a.
26. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667-2674.
27. Robb-Smith AH. U.S. National Cancer Institute working formulation of non-Hodgkin's lymphomas for clinical use. Lancet. 1982;2:432-434.
28. Harris NL. Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group). Ann Oncol. 1997;8:11-16.
29. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
30. A Handbook for Reporting Results of Cancer Treatment. Vol. 38. Geneva, Switzerland: World Health Organization; 1979.
31. Lamy T, Drenou B, Grulois I, et al. Improvement of hematologic recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF. Ann Hematol. 1994;69:297-302.
32. Linassier C, Desablens B, Lefrancq T, et al. Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma. 2002;3:167-172.
33. Kaplan E MP. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
34. Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood. 2002;100:1141-1152.
35. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325-3333.
36. van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521-3529.
37. McQuaker IG, Haynes AP, Anderson S, et al. Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. J Clin Oncol. 1997;15:2288-2295.
38. Voso MT, Hohaus S, Moos M, Haas R. Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma. Blood. 1997;89:3763-3768.
39. Voso MT, Hohaus S, Moos M, et al. Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br J Haematol. 1999;104:382-391.
40. Gribben JG, Saporito L, Barber M, et al. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood. 1992;80:1083-1089.
41. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357.
42. Howe R, Micallef IN, Inwards DJ, et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant. 2003;32:317-324.
43. Mounier N, Socie G, Gisselbrecht C. High-dose therapy for indolent lymphoma. Crit Rev Oncol Hematol. 2002;41:225-239.
44. Lenz G, Unterhalt M, Haferlach T, Hiddemann W, Dreyling M. Significant increase of secondary myelodysplasia and acute myeloid leukemia after myeloablative radiochemotherapy followed by autologous stem cell transplantation in indolent lymphoma patients: results of a prospective randomized study for the GLSG [abstract]. Blood. 2003;102:986a.